Literature DB >> 8618668

Focal temporal lobe dysfunction in probable Alzheimer's disease predicts a slow rate of cognitive decline.

M A Butters1, O L Lopez, J T Becker.   

Abstract

The memory disorder in Alzheimer's disease (AD) can be described as having two components: one primarily a defect in secondary memory and the other a defect in executive processes. We compared and contrasted the pattern of neuropsychological impairment in AD patients as a function of their memory and executive deficits. A K-Means cluster analysis identified four groups of patients. All four groups had impaired episodic and semantic memory and three had progressively more severe impairments in executive functions. The fourth group had normal executive functions; this group (N=32), described as having a "temporal lobe" pattern of impairment, had a significantly slower rate of progression of their dementia, with visual-construction skills virtually spared. These data demonstrate the existence of a subgroup of AD patients with a consistent pattern of impairment who progress more slowly than other patients over the course of 2 years and who maintain some specific cognitive abilities. This suggests that the mechanism of their disease may be different.

Entities:  

Mesh:

Year:  1996        PMID: 8618668     DOI: 10.1212/wnl.46.3.687

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs.

Authors:  Young Noh; Seun Jeon; Jong Min Lee; Sang Won Seo; Geon Ha Kim; Hanna Cho; Byoung Seok Ye; Cindy W Yoon; Hee Jin Kim; Juhee Chin; Kee Hyung Park; Kenneth M Heilman; Duk L Na
Journal:  Neurology       Date:  2014-10-24       Impact factor: 9.910

2.  Brain perfusion abnormalities in Alzheimer's disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment.

Authors:  A Cappa; M L Calcagni; G Villa; A Giordano; C Marra; G De Rossi; M Puopolo; G Gainotti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

3.  Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.

Authors:  Alistair Burns; Andrew Yeates; Latif Akintade; Megan Del Valle; Richard Y Zhang; Elias M Schwam; Carlos A Perdomo
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  Profiling heterogeneity of Alzheimer's disease using white-matter impairment factors.

Authors:  Xiuchao Sui; Jagath C Rajapakse
Journal:  Neuroimage Clin       Date:  2018-10-29       Impact factor: 4.881

Review 5.  Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome.

Authors:  Benjamin Lam; Mario Masellis; Morris Freedman; Donald T Stuss; Sandra E Black
Journal:  Alzheimers Res Ther       Date:  2013-01-09       Impact factor: 6.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.